[Efficacy and Safety of Blinatumomab in Adult Patients with B-Cell Acute Lymphoblastic Leukemia].

OBJECTIVE: To evaluate the efficacy and safety of blinatumomab in adult patients with relapsed/refractory (R/R) or measurable residual disease (MRD) positive B-cell acute lymphoblastic leukemia (B-ALL) in the real world. METHODS: ), overall survival (OS), and disease-free survival (DFS), as well as drug-related adverse reactions. RESULTS: group. The median DFS of the two groups were not reached. Drug-related adverse reactions occurred in 22 patients, and pyrexia was the most common (13 cases). Grade ≥3 adverse reactions occurred in 15 patients, and neutropenia was the most common (9 cases). Cytokine release syndrome occurred in 6 patients, including 5 cases with grade 1 and 1 case with grade 3. No patients interrupted therapy or died due to drug-related adverse reactions. CONCLUSION: B-ALL with acceptable adverse reactions.